Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma

全面的分子特征分析揭示了肾髓质癌独特的基因组和免疫学特征

阅读:7
作者:Pavlos Msaouel ,Gabriel G Malouf ,Xiaoping Su ,Hui Yao ,Durga N Tripathi ,Melinda Soeung ,Jianjun Gao ,Priya Rao ,Cristian Coarfa ,Chad J Creighton ,Jean-Philippe Bertocchio ,Selvi Kunnimalaiyaan ,Asha S Multani ,Jorge Blando ,Rong He ,Daniel D Shapiro ,Luigi Perelli ,Sanjana Srinivasan ,Federica Carbone ,Patrick G Pilié ,Menuka Karki ,Riyad N H Seervai ,Bujamin H Vokshi ,Dolores Lopez-Terrada ,Emily H Cheng ,Ximing Tang ,Wei Lu ,Ignacio I Wistuba ,Timothy C Thompson ,Irwin Davidson ,Virginia Giuliani ,Katharina Schlacher ,Alessandro Carugo ,Timothy P Heffernan ,Padmanee Sharma ,Jose A Karam ,Christopher G Wood ,Cheryl L Walker ,Giannicola Genovese ,Nizar M Tannir

Abstract

Renal medullary carcinoma (RMC) is a highly lethal malignancy that mainly afflicts young individuals of African descent and is resistant to all targeted agents used to treat other renal cell carcinomas. Comprehensive genomic and transcriptomic profiling of untreated primary RMC tissues was performed to elucidate the molecular landscape of these tumors. We found that RMC was characterized by high replication stress and an abundance of focal copy-number alterations associated with activation of the stimulator of the cyclic GMP-AMP synthase interferon genes (cGAS-STING) innate immune pathway. Replication stress conferred a therapeutic vulnerability to drugs targeting DNA-damage repair pathways. Elucidation of these previously unknown RMC hallmarks paves the way to new clinical trials for this rare but highly lethal malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。